Cargando…

Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China

BACKGROUND: Previous studies on cancer of unknown primary (CUP) mainly focus on treatment and prognosis in western populations and lacked clinical evaluation of different IHC markers, so this study aimed to evaluate characteristics of CUP and recommend a diagnostic strategy from a single center in C...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Min, Cai, Xu, Jia, Liqing, Bai, Qianming, Zhu, Xiaoli, Hu, Xichun, Wang, Qifeng, Luo, Zhiguo, Zhou, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691136/
https://www.ncbi.nlm.nih.gov/pubmed/38041048
http://dx.doi.org/10.1186/s12885-023-11563-1
_version_ 1785152678727254016
author Ren, Min
Cai, Xu
Jia, Liqing
Bai, Qianming
Zhu, Xiaoli
Hu, Xichun
Wang, Qifeng
Luo, Zhiguo
Zhou, Xiaoyan
author_facet Ren, Min
Cai, Xu
Jia, Liqing
Bai, Qianming
Zhu, Xiaoli
Hu, Xichun
Wang, Qifeng
Luo, Zhiguo
Zhou, Xiaoyan
author_sort Ren, Min
collection PubMed
description BACKGROUND: Previous studies on cancer of unknown primary (CUP) mainly focus on treatment and prognosis in western populations and lacked clinical evaluation of different IHC markers, so this study aimed to evaluate characteristics of CUP and recommend a diagnostic strategy from a single center in China. METHODS AND RESULTS: Data of 625 patients with CUP were retrospectively collected and reviewed. The patients ranged in age from 20 to 91 years, with a female-to-male ratio of 1.3:1. The predominant histological type was poor or undifferentiated adenocarcinomas (308; 49.3%). The results of Canhelp-Origin molecular testing for the identification of the tissue of origin in 262 of 369 patients (71.0%) were considered predictable (similarity score > 45), with the most common predicted primary tumor site being the breast (57, 21.8%). Unpredictable molecular results correlated with more aggressive clinical parameters and poor survival. Thee positivity rates of several targeted antibodies (GATA3, GCDFP15, TTF1, Napsin A, and PAX8), based on the clinically predicted site, were lower than those reported for the corresponding primary tumors. Nonetheless, TRPS1 and INSM1 were reliable markers of predicted breast carcinoma (75.0%) and neuroendocrine tumors (83.3%), respectively. P16 expression, as well as HPV and EBER testing contributed significantly to the diagnosis of squamous cell carcinomas. Survival analysis revealed that older ages (> 57), ≥ 3 metastatic sites, non-squamous cell carcinomas, bone/liver/lung metastases, unpredictable molecular results, and palliative treatment correlated with poor overall survival. CONCLUSIONS: We recommend a CUP diagnostic strategy involving the use of targeted antibody panels as per histological findings that is potentially applicable in clinical practice. The markers TRPS1, INSM1, and P16 expression, as well as HPV and EBER testing are particularly valuable in this aspect. Molecular testing is also predictive of survival rates.
format Online
Article
Text
id pubmed-10691136
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106911362023-12-02 Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China Ren, Min Cai, Xu Jia, Liqing Bai, Qianming Zhu, Xiaoli Hu, Xichun Wang, Qifeng Luo, Zhiguo Zhou, Xiaoyan BMC Cancer Research BACKGROUND: Previous studies on cancer of unknown primary (CUP) mainly focus on treatment and prognosis in western populations and lacked clinical evaluation of different IHC markers, so this study aimed to evaluate characteristics of CUP and recommend a diagnostic strategy from a single center in China. METHODS AND RESULTS: Data of 625 patients with CUP were retrospectively collected and reviewed. The patients ranged in age from 20 to 91 years, with a female-to-male ratio of 1.3:1. The predominant histological type was poor or undifferentiated adenocarcinomas (308; 49.3%). The results of Canhelp-Origin molecular testing for the identification of the tissue of origin in 262 of 369 patients (71.0%) were considered predictable (similarity score > 45), with the most common predicted primary tumor site being the breast (57, 21.8%). Unpredictable molecular results correlated with more aggressive clinical parameters and poor survival. Thee positivity rates of several targeted antibodies (GATA3, GCDFP15, TTF1, Napsin A, and PAX8), based on the clinically predicted site, were lower than those reported for the corresponding primary tumors. Nonetheless, TRPS1 and INSM1 were reliable markers of predicted breast carcinoma (75.0%) and neuroendocrine tumors (83.3%), respectively. P16 expression, as well as HPV and EBER testing contributed significantly to the diagnosis of squamous cell carcinomas. Survival analysis revealed that older ages (> 57), ≥ 3 metastatic sites, non-squamous cell carcinomas, bone/liver/lung metastases, unpredictable molecular results, and palliative treatment correlated with poor overall survival. CONCLUSIONS: We recommend a CUP diagnostic strategy involving the use of targeted antibody panels as per histological findings that is potentially applicable in clinical practice. The markers TRPS1, INSM1, and P16 expression, as well as HPV and EBER testing are particularly valuable in this aspect. Molecular testing is also predictive of survival rates. BioMed Central 2023-12-01 /pmc/articles/PMC10691136/ /pubmed/38041048 http://dx.doi.org/10.1186/s12885-023-11563-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ren, Min
Cai, Xu
Jia, Liqing
Bai, Qianming
Zhu, Xiaoli
Hu, Xichun
Wang, Qifeng
Luo, Zhiguo
Zhou, Xiaoyan
Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China
title Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China
title_full Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China
title_fullStr Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China
title_full_unstemmed Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China
title_short Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China
title_sort comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691136/
https://www.ncbi.nlm.nih.gov/pubmed/38041048
http://dx.doi.org/10.1186/s12885-023-11563-1
work_keys_str_mv AT renmin comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina
AT caixu comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina
AT jialiqing comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina
AT baiqianming comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina
AT zhuxiaoli comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina
AT huxichun comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina
AT wangqifeng comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina
AT luozhiguo comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina
AT zhouxiaoyan comprehensiveanalysisofcancerofunknownprimaryandrecommendationofahistologicalandimmunohistochemicaldiagnosticstrategyfromchina